Physician profile
Henry Lin
NPI 1407966500
$6,714.02
in general payments reported to CMS, 2019-2025
24 companies · $773 in 2025
The $773 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $293 · 2021: $489 · 2022: $560 · 2023: $541 · 2024: $3,392 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,514 · Food and Beverage: $2,177 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,514.40 |
| Food and Beverage | $2,177.19 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $2,871.44 | 2019-2024 | Hizentra |
| Genzyme Corporation | $1,018.03 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $415.89 | 2019-2025 | Dupixent, Eylea Hd |
| Glaxosmithkline, LLC. | $382.14 | 2019-2025 | Nucala, Trelegy Ellipta |
| Octapharma USA, INC. | $290.08 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $252.09 | 2019-2024 | Airsupra, Breztri, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $247.60 | 2021-2025 | Takhzyro, Cuvitru, Hyqvia |
| Grifols USA, LLC | $228.62 | 2020-2025 | Xembify |
| Leo Pharma INC. | $182.66 | 2022-2025 | Adbry |
| Amgen INC. | $172.01 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $117.42 | 2021-2025 | |
| Pfizer INC. | $114.61 | 2022-2025 | |
| Abbvie INC. | $84.13 | 2022-2023 | |
| Allergan, INC. | $50.38 | 2022 | |
| Incyte Corporation | $43.54 | 2021-2024 | Opzelura |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $42.84 | 2019-2021 | |
| Lilly USA, LLC | $42.13 | 2025 | Ebglyss, Taltz |
| Optinose US, INC. | $37.10 | 2025 | |
| Pharming Healthcare, INC. | $25.68 | 2020 | |
| Shire North American Group INC | $25.34 | 2019 | |
| Greer Laboratories, INC. | $24.93 | 2025 | Palforzia |
| Galderma Laboratories, L.P. | $17.70 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $14.60 | 2023 | Ryaltris |
| Sientra, INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.